LAEKNA-B(02105): Ke Chenyu's qualification as company secretary has been confirmed by the Hong Kong Stock Exchange.
Kaily Pharmaceuticals (02105) announced that the Stock Exchange has confirmed that Mr. Ke Chenyu meets the qualifications to serve as the company secretary under Rules 3.28 and 8.17 of the listing rules.
LAEKNA-B (02105) announcement that the Stock Exchange has confirmed Mr. Ke Chenyu is qualified to serve as the company secretary of the company under listing rule 3.28 and 8.17.
One of the joint company secretaries, Ms. Ho Wing-nga, has resigned as the joint company secretary and authorized representative of the company under the listing rules, effective from June 29, 2026. At the same time, Ms. Ho will continue to serve as the authorized representative of the company for receiving legal process documents and notices in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622).
After Ms. Ho's resignation as joint company secretary, Mr. Ke will continue to serve as the sole company secretary of the company. Mr. Ke has also been appointed as the authorized representative of the company under listing rule 3.05, effective from June 29, 2026.
Related Articles
NEW CONCEPTS (02221) Announces Annual Performance, Shareholders' loss of HKD 58.364 million, a 27.7% year-on-year reduction.
CULTURECOM HOLD (00343) issued a profit warning, expecting an annual net loss of approximately HK$45 million to HK$55 million, an increase compared to the previous year.
JOLIMARK (02028) plans to offer a discount of approximately 19.1% for the sale of up to 122.6 million shares, raising approximately HK$86.4 million.
NEW CONCEPTS (02221) Announces Annual Performance, Shareholders' loss of HKD 58.364 million, a 27.7% year-on-year reduction.
CULTURECOM HOLD (00343) issued a profit warning, expecting an annual net loss of approximately HK$45 million to HK$55 million, an increase compared to the previous year.
JOLIMARK (02028) plans to offer a discount of approximately 19.1% for the sale of up to 122.6 million shares, raising approximately HK$86.4 million.
RECOMMEND
